Renaissance Technologies (RenTech)'s PHAT Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 305,800 shares of Phathom Pharmaceuticals, Inc. (PHAT) worth $3.4 M, representing 0.01% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in PHAT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 305,800 shares. Largest reduction occurred in Q1 2024, reducing 65,600 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Phathom Pharmaceuticals (PHAT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Phathom Pharmaceuticals (PHAT) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +305,800 | New Buy | 305,800 | $11.11 |
| Q1 2024 | -65,600 | Sold Out | 0 | $0.00 |
| Q4 2023 | +65,600 | New Buy | 65,600 | $9.13 |
| Q3 2023 | -10,000 | Sold Out | 0 | $0.00 |
| Q2 2023 | +10,000 | New Buy | 10,000 | $0.01 |
| Q3 2022 | -24,000 | Sold Out | 0 | $0.00 |
| Q2 2022 | +24,000 | New Buy | 24,000 | $8.46 |
| Q2 2021 | -11,300 | Sold Out | 0 | $0.00 |
| Q1 2021 | +11,300 | New Buy | 11,300 | $37.52 |
Renaissance Technologies (RenTech)'s Phathom Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Phathom Pharmaceuticals, Inc. (PHAT) in Q1 2021, acquiring 11,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Phathom Pharmaceuticals, Inc. (PHAT) for 9 quarters since Q1 2021.
Renaissance Technologies (RenTech)'s largest addition to Phathom Pharmaceuticals, Inc. (PHAT) was in Q1 2026, adding 305,800 shares worth $3.4 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 305,800 shares of Phathom Pharmaceuticals, Inc. (PHAT), valued at approximately $3.4 M.
As of the Q1 2026 filing, Phathom Pharmaceuticals, Inc. (PHAT) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Phathom Pharmaceuticals, Inc. (PHAT) was 305,800 shares, as reported at the end of Q1 2026.